Connect with us

Hi, what are you looking for?

Investing

Completion of preclinical data package for RAD 402

Published

Radiopharm Theranostics (RAD:AU) has announced Completion of preclinical data package for RAD 402

Download the PDF here.

This post appeared first on investingnews.com
In this article:







    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!



    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    You May Also Like

    Investing

    10 Biggest Cannabis Stocks in the US and Canada in 2024

    During the second quarter of 2024, the cannabis sector encountered a familiar set of challenges that have persisted for the past two years, with...

    August 9, 2024

    Stock

    UAW members approve 4½-year contract with Detroit’s Big Three

    Union members at Ford, Stellantis and General Motors have ratified a new 4½-year contract, locking in at 11% pay increases secured after a six-week...

    November 17, 2023

    Editor's Pick

    The history behind a Laphonza Butler Senate appointment

    California Gov. Gavin Newsom announced Sunday that he was appointing Emily’s List President Laphonza Butler as the replacement to former senator Dianne Feinstein (D-Calif.),...

    October 3, 2023

    Editor's Pick

    Iran launches massive drone and missile attack against Israel

    JERUSALEM — Iran launched a massive attack of more than 300 missiles and drones toward Israel late Saturday, a stunning assault that put the...

    April 14, 2024

    Disclaimer: investmentintellecthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2024 InvestmentIntellectHub.com